SMMT Valuation

Summit Therapeutics Inc

Add to Watchlist

Advanced Chart

17.360

-1.550(-8.200%)

Overview
Forecast
Valuation

SMMT Relative Valuation

SMMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SMMT is overvalued; if below, it's undervalued.

Historical Valuation

Summit Therapeutics Inc(SMMT) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of317.55.The fair price of Summit Therapeutics Inc(SMMT)is betweenNaNtoNaNaccording to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：17.36

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

36.60

P/B

Median3y

25.06

Median5y

18.45

-0.95

FCF Yield

Median3y

-12.57

Median5y

-13.63

Competitors Valuation Multiple

The average P/S ratio for SMMT's competitors is 4.00, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appearsunsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

SMMT.O

Summit Therapeutics Inc

Loss

Average P/S: 4.00

5.52B